Drug Profile
GPI 1216
Latest Information Update: 27 Sep 2001
Price :
$50
*
At a glance
- Originator MGI GP
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 27 Sep 2001 Guilford has regained exclusive worldwide rights to the neuroimmunophilin ligand programme from Amgen
- 22 Dec 2000 Discontinued-Preclinical for Neurological disorders (Prevention) in USA (Unknown route)
- 27 Nov 1997 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)